<DOC>
	<DOCNO>NCT00821444</DOCNO>
	<brief_summary>Commercial ziprasidone capsule show large increase bioavailability food . The formulation test study aim reduce eliminate increase .</brief_summary>
	<brief_title>Ziprasidone Pharmacokinetics Using Reduced Food Effect Formulation Compared Pharmacokinetics From Commercial Capsules</brief_title>
	<detailed_description />
	<mesh_term>Ziprasidone</mesh_term>
	<criteria>Healthy subject Signed informed consent document Any significant physical psychological disease Concomitant administration pharmaceutical</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>April 2011</verification_date>
	<keyword>schizophrenia , pharmacokinetics , bioavailability , food effect</keyword>
</DOC>